TITLE

Emerging treatment combinations: Integrating therapy into clinical practice

AUTHOR(S)
Wong, Serena T.
PUB. DATE
December 2009
SOURCE
American Journal of Health-System Pharmacy;12/2/2009, Issue S6, pS9
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses research regarding combination drug treatments for metastatic breast cancer. Signal-transduction pathways play a key role in the development of breast cancer and medical research has been focusing on immunosuppressant agents such as everolimus. Epidermal growth factor receptor (EGFR) has been studied to determine its role in resistance to endocrine therapy, as well as the role of epigenetic gene silencing in modifying the expression of tumor-suppressing genes.
ACCESSION #
47627663

 

Related Articles

  • Untitled.  // JNCI: Journal of the National Cancer Institute;Aug2015, Vol. 107 Issue 8, p8 

    The article reports on two studies that explore the use of the cyclin-dependent kinase 4/6 inhibitor palbociclib for treating cancer. Topics discussed include a randomized phase 2 study which dealt on the use of the palbociclib in combination with letrozole versus letrozole alone as first-line...

  • BIG 1-98: Adjuvant letrozole reduced risk for death, recurrence compared with tamoxifen. Zelnak, Amelia; Fisher, Stacey L.; Harris, Jason; McKnight, Whitney // Hem/Onc Today;4/10/2011, Vol. 12 Issue 7, p22 

    The article reports on a study which found that women with breast cancer who were given adjuvant letrozole showed reduced risk for death and recurrence compared with tamoxifen.

  • The role of raltitrexed/cisplatin with concurrent radiation therapy in treating advanced cervical cancer. LI, X.-Y.; LIU, L.; XIE, X.-M.; ZHOU, C. // European Review for Medical & Pharmacological Sciences;Nov2014, Vol. 18 Issue 22, p3491 

    OBJECTIVE: To explore the effectiveness and safety of raltitrexed/cisplatin with concurrent radiotherapy in treating of patients with advanced cervical cancer. PATIENTS AND METHODS: Sixty-five patients with stage IIB-IVA cervical cancer enrolled in this study, received raltitrexed/cisplatin with...

  • SC-2001 Overcomes STAT3-mediated Sorafenib Resistance through RFX-1/SHP-1 Activation in Hepatocellular Carcinoma. Jung-Chen Su; Ping-Hui Tseng; Szu-Hsien Wu; Cheng-Yi Hsu; Wei-Tien Tai; Yong-Shi Li; I-Ting Chen; Chun-Yu Liu; Kuen-Feng Chen; Chung-Wai Shiau // Neoplasia;Jul2014, Vol. 16 Issue 7, p595 

    Hepatocellular carcinoma is the fifth most common solid cancer worldwide. Sorafenib, a small multikinase inhibitor, is the only approved therapy for advanced HCC. The clinical benefit of sorafenib is offset by the acquisition of sorafenib resistance. Understanding of the molecular mechanism of...

  • Pharmacological modulation of anti-tumor immunity induced by oncolytic viruses. Forbes, Nicole E.; Krishnan, Ramya; Diallo, Jean-Simon // Frontiers in Oncology;Jul2014, Vol. 4, p1 

    Oncolytic viruses (OVs) not only kill cancer cells by direct lysis but also generate a significant anti-tumor immune response that allows for prolonged cancer control and in some cases cures. Howto best stimulate this effect is a subject of intense investigation in the OV field. While...

  • Colorectal Cancer: To Stack or Sequence Therapy? Azvolinsky, Anna // JNCI: Journal of the National Cancer Institute;5/13/2015, Vol. 107 Issue 5, p6 

    The article discusses the findings of the Triplet plus Bevacizumab (TRIBE) study which were presented at the 2015 Gastrointestinal Cancers Symposium in January. Topics discussed include the effectiveness of a triplet combination chemotherapy plus bevacizumab in lowering risk of progression in...

  • OncotypeDX-guided treatment of breast cancer cost effective.  // PharmacoEconomics & Outcomes News;6/2/2007, Issue 529, p12 

    The article discusses research being done on the OncotypeDX-guided treatment of breast cancer. It references a study by G. H. Lyman et al published in the March 15, 2007 issue of "Cancer." According to U.S. researchers, treatment decisions based on the OncotypeDX recurrence score are associated...

  • Effect of Paullinia cupana on MCF-7 breast cancer cell response to chemotherapeutic drugs. HERTZ, EVERALDO; CADONÁ, FRANCINE CARLA; MACHADO, ALENCAR KOLINSKI; AZZOLIN, VERÔNICA; HOLMRICH, SABRINA; ASSMANN, CHARLES; LEDUR, PAULINE; ESTEVES RIBEIRO, EULER; DE SOUZA FILHO, OLMIRO CEZIMBRA; MANICA-CATTANI, MARIA FERNANDA; MÂNICA DA CRUZ, IVANA BEATRICE // Molecular & Clinical Oncology;2015, Vol. 3 Issue 1, p37 

    Previous studies suggested that certain plants, such as guarana (Paullinia cupana), exert a protective effect against cancer-related fatigue in breast cancer patients undergoing chemotherapy. However, guarana possesses bioactive molecules, such as caffeine and catechin, which may affect the...

  • Combination of cetuximab and PP242 synergistically suppress the progression of wild-type KRAS colorectal carcinoma. Lei Cheng; Zuguang Xia; Xinyu Bian; Guangchao Li; Jing Hu; Ya Cao; Qing Wang; Xiaoping Qian // OncoTargets & Therapy;Nov2015, Vol. 8, p3185 

    Mammalian target of rapamycin (mTOR) has been shown to be overactive in human colorectal cancer, but the first-generation mTOR inhibitor, rapamycin, has failed to show clinical efficacy against colorectal cancer. On the other hand, although the secondgeneration mTOR inhibitor, PP242, has exerted...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics